Adults aged 18 years or older with a diagnosis of hidradenitis suppurativa (HS) for at least 6 months, may qualify to participate. Individuals must have HS lesions present in at least 2 distinct areas of the body. Moderate to severe disease with at least 5 inflammatory nodules or abscesses, must be present. Inadequate response to a course of a systemic antibiotic for the treatment of HS, is also required.
Participants will receive investigational medication (active study drug) or placebo, via injection. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.
Study participation will last about 71 weeks and involve about 28 visits to the study centre.